Stockreport

uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies

uniQure N.V. - Ordinary Shares  (QURE) 
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: uniqure.com/investors-newsroom/overview.php
PDF -- New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 -- -- Data Suggest AAV5 Gene Therapies May be Viable Treatments for at Least 97% of Patients [Read more]